Reporting Summary Supplementary Table The list of differentially expressed genes between PD-1WT and PD-1KO Treg cells in the same tumor of isotype-treated TC-1 tumor-bearing (as in Extended Data Fig. 10a) PD-1Cre+/− mice at day 14 after injection. Significance of difference in this tabl...
Reporting Summary Rights and permissions Reprints and permissions About this article Cite this article Zhao, P., Wang, P., Dong, S. et al. Depletion of PD-1-positive cells ameliorates autoimmune disease. Nat Biomed Eng 3, 292–305 (2019). https://doi.org/10.1038/s41551-019-0360-0 Downl...
In summary, tumours will be resistance to PD-1/PD-L1 blockade if there are insufficient numbers of tumour-specific effector T-cells in the patient, or if these cells are unable to enter the TME to execute their anti-tumour activities. 6.3. Expression of PD-1 ligands A key requirement for...
In summary, both GEMSTONE-302 and GEMSTONE-301 provide convincing results for the population of China. Notably, the results of GEMSTONE-302 are similar to those demonstrated for currently approved agents in the US, it is possible to believe that it applies to the western population[180]. 4...
Panobinostat, a potent pan-deacetylase inhibitor, improved progression-free survival (PFS) in patients with relapsed and refractory multiple myeloma when combined with bortezomib and dexamethasone in a phase 3 trial, PANORAMA-1. This study aims to explore exposure–response relationship for panobinostat ...
2F and G). In summary, with increasing concentrations of CoCl2, the proliferation and migration capabilities of TNBC cells is significantly inhibited. Fig. 2 Biological behavior changes of TNBC cells under hypoxic conditions. (A) Cell counting method to evaluate the effect of different concentrations...
Aside from PD-L1 expression, biomarkers of response to immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer (NSCLC) are needed. In a previous retrospective analysis, we documented that fecal Akkermansia muciniphila (Akk) was associated with
Supplementary Methods, Supplementary Tables 1–3 & Supplementary Figures 1–17 (PDF 7906 kb) Life Sciences Reporting Summary (PDF 213 kb) Rights and permissions Reprints and permissions About this article Cite this article Krieg, C., Nowicka, M., Guglietta, S.et al.High-dimensional single-cell...
SUMMARY This disclosure relates to anti-PD-1 antibodies, antigen-binding fragment thereof, and the uses thereof. In one aspect, the disclosure relates to an antibody or antigen-binding fragment thereof that binds to PD-1 (Programmed Cell Death Protein 1) comprising: a heavy chain variable region...
SUMMARY One of the technical issues to be solved by the invention is to provide a novel anti-PD-1 McAb or a derivative thereof such as antibody Fab fragment and single-chain antibody, with antigen binding domains or epitopes different from those of current Opdivo (Nivolumab) or Keytruda (Pemb...